Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Capital Employed (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Return on Capital Employed for 11 consecutive years, with 0.56% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed rose 91.0% year-over-year to 0.56%, compared with a TTM value of 0.56% through Sep 2025, up 91.0%, and an annual FY2024 reading of 0.87%, up 34.0% over the prior year.
  • Return on Capital Employed was 0.56% for Q3 2025 at Avalo Therapeutics, down from 0.49% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.36% in Q1 2024 and bottomed at 2.92% in Q4 2022.
  • Average Return on Capital Employed over 5 years is 1.56%, with a median of 1.38% recorded in 2023.
  • The sharpest move saw Return on Capital Employed crashed -171bps in 2022, then skyrocketed 255bps in 2024.
  • Year by year, Return on Capital Employed stood at 1.21% in 2021, then crashed by -141bps to 2.92% in 2022, then surged by 54bps to 1.33% in 2023, then soared by 56bps to 0.58% in 2024, then grew by 3bps to 0.56% in 2025.
  • Business Quant data shows Return on Capital Employed for AVTX at 0.56% in Q3 2025, 0.49% in Q2 2025, and 0.36% in Q1 2025.